IGC Pharma Expands Phase 2 CALMA Trial for IGC-AD1 at BayCare’s St. Anthony’s Hospital
IGC Pharma, a leading biopharmaceutical company, announced on March 17, 2025, the addition of a new trial site at BayCare’s St. Anthony’s Hospital in St. Petersburg, Florida, as part of its ongoing Phase 2 CALMA (Calming Agitation with IGC-AD1 in Alzheimer’s Dementia) trial. IGC-AD1 is the Company’s lead therapeutic candidate designed to address agitation in Alzheimer’s disease.
What is IGC-AD1 and what does it aim to do?
IGC-AD1 is a combination therapy developed by IGC Pharma to address agitation in Alzheimer’s disease. Agitation is a common and distressing symptom experienced by many Alzheimer’s patients, which can significantly impact their quality of life and that of their caregivers. IGC-AD1 is designed to provide a safe and effective treatment option for this debilitating symptom.
Expansion of the CALMA trial
With the addition of BayCare’s St. Anthony’s Hospital as a trial site, the CALMA trial now includes six sites across the United States. This expansion will allow the Company to enroll more patients and gather more data on the safety and efficacy of IGC-AD1 in treating agitation in Alzheimer’s disease. The trial is expected to be completed by the end of 2025.
Impact on patients and caregivers
For patients with Alzheimer’s disease and their caregivers, the expansion of the CALMA trial is an encouraging sign. Agitation is a challenging symptom to manage, and current treatment options often come with significant side effects or limited efficacy. IGC-AD1, with its combination therapy approach, offers the potential for a more effective and safer treatment option. Successful outcomes from the CALMA trial could lead to IGC-AD1 becoming an approved therapy for agitation in Alzheimer’s disease, providing much-needed relief for patients and their caregivers.
Global implications
The expansion of the CALMA trial is not only significant for patients and their families in the United States but also for the global Alzheimer’s community. Alzheimer’s disease is a global health issue, affecting millions of people worldwide. The successful development of IGC-AD1 as a treatment for agitation could lead to its approval and availability in other countries, making a positive impact on the lives of countless individuals and their families.
Conclusion
IGC Pharma’s expansion of the CALMA trial at BayCare’s St. Anthony’s Hospital is an exciting step forward in the development of IGC-AD1 as a treatment for agitation in Alzheimer’s disease. With the potential to provide a safe and effective treatment option, IGC-AD1 could significantly improve the quality of life for patients and their caregivers. The global implications of this development are vast, as Alzheimer’s disease is a global health issue affecting millions. The successful completion of the CALMA trial could lead to the approval and availability of IGC-AD1 in countries around the world, offering hope and relief to those in need.
- IGC Pharma expands CALMA trial to BayCare’s St. Anthony’s Hospital in St. Petersburg, Florida
- IGC-AD1 is a combination therapy designed to address agitation in Alzheimer’s disease
- Expansion allows for enrollment of more patients and gathering of more data
- Successful outcomes could lead to IGC-AD1 becoming an approved therapy for agitation in Alzheimer’s disease
- Global implications include potential availability in other countries
